“…use of large, representative highand low-risk samples, to strengthen the generalizability of findings use of meaningful end points (eg, validated diagnostic measures to assess for ASD and other developmental disorders, as well as an increased focus on outcomes of greatest relevance to families and to the health system, such as age of diagnosis, age of entry into intervention, and long-term developmental gains resulting from screening) inclusion of systematic surveillance methods, as well as followup tracking of screen-negative cases, to improve estimates of sensitivity, specificity, and NPV evaluation of different scoring approaches (categorical versus continuous) and, potentially, different age-specific scoring algorithms for specific ages, to further optimize screening strategies that might be implemented longitudinally reporting of detailed characterizations of study participants, including social factors, cognitive level, and medical history, to improve comparisons across studies and to better understand what factors might influence the accuracy of screening for individual children evaluation of potential differences between screen-positive children who are seen for a diagnostic assessment and those who do not complete follow-up (which is often in the range of 25%-40% 25,27 and in some studies exceeds 50% 17 ) to further evaluate potential barriers and facilitators, and provide information essential to evaluating the generalizability of study findings inclusion of underrepresented minority and historically underserved groups, to help ensure representative samples and the development of culturally appropriate adaptations of screening tools for such populations…”